BioContact Quebec Presentation Same Day
WALTHAM, Mass., Oct. 4 /PRNewswire/ -- AltaRex Corp. (AXO.TO, ALXFF.OTC)
today announced that the Company will present at the UBS Warburg Global Life
Sciences Conference on Thursday, October 11, 2001 at 11:20 a.m. The
conference is being held at The Pierre Hotel in New York City. On the same
day at 9:30 a.m., AltaRex will also be presenting at BioContact Quebec, which
is being held at the Chateau Frontenac in Quebec City.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000831/ALTREXLOGO )
The investing public is invited by Richard Bagley, President and CEO of
AltaRex, to participate in the UBS Warburg presentation through a listen-only
conference call, by dialing 800-500-0177 (domestic) or 719-457-2679
(international). Replays will be available for up to four weeks following the
conference and can be accessed by dialing 888-566-0785 (domestic) or
402-220-0102 (international).
AltaRex Corp. is focused on the research, development and
commercialization of antigen-targeted antibody-based cancer therapies,
utilizing monoclonal antibodies as immunotherapeutic agents for the treatment
of certain late-stage cancers. AltaRex's lead product OvaRex(R) MAb targets
the tumor associated antigen CA 125 and is being studied for the treatment of
advanced ovarian cancer. The Company has completed its pivotal 345-patient
OvaRex(R) trial (phase IIb) for primary analysis of efficacy and has completed
and reported results from several supporting trials. The Company expects to
initiate its first Biologics License Application (BLA) for regulatory approval
of OvaRex(R) MAb by the U.S. Food and Drug Administration (FDA) early in 2002,
assuming timely scale-up of cell culture manufacturing. The opportunity for
approval on the basis of phase II/IIb studies stems from Orphan Drug and Fast
Track provisions granted OvaRex(R) by the FDA for its potential to fill an
unmet medical need; there are no approved treatment options for patients in
the remittive or "watchful waiting" period of ovarian cancer, prior to disease
recurrence. The compilation of OvaRex(R) data from six clinical studies in
over 500 ovarian cancer patients is expected to form the basis of the
OvaRex(R) BLA, for which AltaRex will seek priority review and full and/or
accelerated approval of the antibody.
More about AltaRex research and development of antigen-targeted anti-
cancer antibodies, clinical trials, news and events can be found on its web
site at http://www.altarex.com. AltaRex Corp. is traded on the Toronto Stock
Exchange under the symbol AXO, and over-the-counter in the United States under
the symbol ALXFF.
This news release contains forward-looking statements that involve risks
and uncertainties, which may cause actual results to differ materially from
the statements made. For this purpose, any statements that are contained
herein that are not statements of historical fact may be deemed to be forward-
looking statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "intends," "expects" and similar expressions are
intended to identify forward-looking statements. Such risks and uncertainties
include, but are not limited to our need for capital and the risk that the
Company can not raise funds on a timely basis on satisfactory terms or at all,
changing market conditions, uncertainties regarding the timely and successful
completion of clinical trials, patient enrollment rates, uncertainty of pre-
clinical, retrospective, early and interim clinical trial results, which may
not be indicative of results that will be obtained in ongoing or future
clinical trials, whether the Company will file for regulatory approval on a
timely basis, uncertainties as to when, if at all, the FDA will approve the
Company's regulatory filings for its products, the need to establish and
scale-up manufacturing processes, the need to obtain and maintain corporate
alliances, uncertainty as to the timely development and market acceptance of
the Company's products, uncertainty as to whether patents will issue from
pending patent applications and, if issued, as to whether such patents will be
sufficiently broad to protect the Company's technology, and other risks
detailed from time-to-time in the Company's filings with the United States
Securities and Exchange Commission and Canadian securities authorities.
THE TORONTO STOCK EXCHANGE HAS NOT APPROVED OR DISAPPROVED OF THE
INFORMATION CONTAINED HEREIN
SOURCE AltaRex Corp.
 back to top
Related links:
http://www.altarex.com
Company News On-Call:
http://www.prnewswire.com/comp/128163.html
CONTACT:
Sondra Henrichon, Director, Investor
Relations and Corporate Communications of AltaRex Corp.,
+1-781-672-0138 ext. 1510, shenrichon@altarex.com; or Wayne
Hendry, Investor Relations of The Equicom Group Inc,
+1-416-815-0700 ext. 238, whendry@equicomgroup.com
|
